TYMS and non-small cell lung carcinoma: It has been previously demonstrated that EGFR TKI, such as erlotinib/or gefitinib treatment with fluoropyrimidine, resulted in an synergistic inhibitory effect in non-small-cell lung cancer cells, possibly as the result of TS downregulation via the inhibition of EGFR signaling [10], [11].